A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer.

MedComm (2020) · 2025 · PMC12696423 · PMID 41394962

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Exploratory analyses showed a trend toward increased T cell receptor (TCR) diversity following treatment.

also in 53,322 other papers

a decreasing trendno p-value reported

The PSI (median difference ‐190.2; 95% CI ‐443.5 to 74.83; p = 0.0938) and polyfunctionality (median difference ‐7.185; 95% CI, ‐24.46 to 5.19; p = 0.1562) of CD8 + T cells also showed a decreasing trend post‐therapy (Figures 3C, D and S4C, D ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.